TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Apixaban for the Treatment of Venous Thromboembolism in Patients With Cancer: A Prospective Randomized Open Blinded End-Point (Probe) Study
Brief Summary: Apixaban for the treatment of venous thromboembolism in patients with cancer: a prospective randomized open blinded end-point (PROBE) study


Options:
A: Arm Label: Apixaban; Type: EXPERIMENTAL; Interventions: Drug: Apixaban | Arm Label: Dalteparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dalteparin | Intervention Type: DRUG; Name: Apixaban; Assigned to Arm(s): Apixaban | Intervention Type: DRUG; Name: Dalteparin; Assigned to Arm(s): Dalteparin
B: Arm Label: dabigatran etexilate 150 mg BID; Type: EXPERIMENTAL; Interventions: Drug: dabigatran etexilate 150 mg twice daily (BID) | Arm Label: matching placebo twice daily (BID); Type: PLACEBO_COMPARATOR; Interventions: Drug: matching placebo twice daily (BID) | Intervention Type: DRUG; Name: dabigatran etexilate 150 mg twice daily (BID); Assigned to Arm(s): dabigatran etexilate 150 mg BID | Intervention Type: DRUG; Name: matching placebo twice daily (BID); Assigned to Arm(s): matching placebo twice daily (BID)
C: Arm Label: heparin/edoxaban tosylate; Type: EXPERIMENTAL; Interventions: Drug: edoxaban tosylate(DU-176b), Drug: low molecular weight heparin/unfractionated heparin | Arm Label: heparin/warfarin; Type: ACTIVE_COMPARATOR; Interventions: Drug: low molecular weight heparin/unfractionated heparin, Drug: warfarin | Intervention Type: DRUG; Name: edoxaban tosylate(DU-176b); Assigned to Arm(s): heparin/edoxaban tosylate | Intervention Type: DRUG; Name: low molecular weight heparin/unfractionated heparin; Assigned to Arm(s): heparin/edoxaban tosylate, heparin/warfarin | Intervention Type: DRUG; Name: warfarin; Assigned to Arm(s): heparin/warfarin
D: Arm Label: Rivaroxaban (Xarelto, BAY59-7939); Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939) | Arm Label: Enoxaparin/VKA; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin followed by VKA | Intervention Type: DRUG; Name: Rivaroxaban (Xarelto, BAY59-7939); Assigned to Arm(s): Rivaroxaban (Xarelto, BAY59-7939) | Intervention Type: DRUG; Name: Enoxaparin followed by VKA; Assigned to Arm(s): Enoxaparin/VKA

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effects and Mechanism of the Sequential Combination of Exercise and Cognitive Training on Cognitive Function in Stroke Patients With Cognitive Decline: A Randomized Controlled Trial
Brief Summary: The purpose of this study is to determine the treatment effects of sequential combination of aerobic exercise and cognitive training on cognitive function, physiological markers, daily function, physical function, social participation and quality of life in stroke patients with cognitive decline.


Options:
A: Arm Label: animal assisted therapy; Type: EXPERIMENTAL; Interventions: Other: animal assisted therapy | Arm Label: standard therapy; Type: ACTIVE_COMPARATOR; Interventions: Other: standard therapy | Intervention Type: OTHER; Name: animal assisted therapy; Assigned to Arm(s): animal assisted therapy | Intervention Type: OTHER; Name: standard therapy; Assigned to Arm(s): standard therapy
B: Arm Label: sequential training group (SEQ); Type: EXPERIMENTAL; Interventions: Behavioral: aerobic exercise training, Behavioral: cognitive training | Arm Label: control intervention group (CI); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: control training | Intervention Type: BEHAVIORAL; Name: aerobic exercise training; Assigned to Arm(s): sequential training group (SEQ) | Intervention Type: BEHAVIORAL; Name: control training; Assigned to Arm(s): control intervention group (CI) | Intervention Type: BEHAVIORAL; Name: cognitive training; Assigned to Arm(s): sequential training group (SEQ)
C: Arm Label: CARET + CTI; Type: EXPERIMENTAL; Interventions: Behavioral: CARET, Behavioral: CTI | Arm Label: Sham CARET + Sham CTI; Type: SHAM_COMPARATOR; Interventions: Behavioral: Sham CARET, Behavioral: Sham CTI | Intervention Type: BEHAVIORAL; Name: CARET; Assigned to Arm(s): CARET + CTI | Intervention Type: BEHAVIORAL; Name: CTI; Assigned to Arm(s): CARET + CTI | Intervention Type: BEHAVIORAL; Name: Sham CARET; Assigned to Arm(s): Sham CARET + Sham CTI | Intervention Type: BEHAVIORAL; Name: Sham CTI; Assigned to Arm(s): Sham CARET + Sham CTI
D: Arm Label: CO-OP; Type: EXPERIMENTAL; Interventions: Behavioral: CO-OP | Arm Label: Attention Control; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Attention Control | Intervention Type: BEHAVIORAL; Name: CO-OP; Assigned to Arm(s): CO-OP | Intervention Type: BEHAVIORAL; Name: Attention Control; Assigned to Arm(s): Attention Control

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Reducing Disability Via a Family-centered Intervention for Acutely-ill Persons With Alzheimer's Disease and Related Dementias
Brief Summary: This study will address the effectiveness of Family-centered Function Focused Care (Fam-FFC). Fam-FFC is a theoretically-based approach to care in which family caregivers partner with nurses to prevent functional decline and other complications related to hospitalization in older adults with Alzheimer's disease and related dementias. A systematic care pathway promotes information-sharing and decision-making that promotes physical activity, function, and cognitive stimulation during the hospitalization and immediate post-acute period. Our goal in this work is to establish a practical and effective way to optimize function and physical activity; decrease neuropsychiatric symptoms, delirium, and depression; prevent avoidable post-acute care dependency; and prevent unnecessary rehospitalizations and long-stay nursing home admissions, while mitigating family caregiver strain and burden.


Options:
A: Arm Label: Usual Care Group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Experimental Group; Type: EXPERIMENTAL; Interventions: Behavioral: a modified NTU-HELP | Intervention Type: BEHAVIORAL; Name: a modified NTU-HELP; Assigned to Arm(s): Experimental Group
B: Arm Label: CPAP therapy arm; Type: EXPERIMENTAL; Interventions: Other: CPAP treatment | Arm Label: Control arm; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: CPAP treatment; Assigned to Arm(s): CPAP therapy arm
C: Intervention Type: PROCEDURE; Name: Orthogeriatric intervention; Assigned to Arm(s): N/A
D: Arm Label: Fam-FFC; Type: EXPERIMENTAL; Interventions: Behavioral: Family-centered Function-focused Care (Fam-FFC) | Arm Label: Attention Control (Fam- FFC Ed-only); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Family-centered Function-focused Care (Fam-FFC); Assigned to Arm(s): Fam-FFC

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Changes in Thyroid Function Tests and Texture Following Bariatric Surgery Induced Weight Loss
Brief Summary: This study is expected to provide novel data regarding potential structural and functional changes of the thyroid gland in morbidly obese adults following significant weight loss through bariatric surgery. These data will complement evidence from epidemiological studies regarding the association of obesity and alterations in thyroid function. Potentially this study may justify further longer-term studies regarding the effects of weight gain and/or weight loss on the morphology of the thyroid gland and could help to form recommendations regarding follow-up investigations for the thyroid in morbidly obese patients.


Options:
A: Arm Label: Enhanced Usual Care (EUC); Type: OTHER; Interventions: Other: EUC | Arm Label: THPP-P; Type: EXPERIMENTAL; Interventions: Behavioral: THPP-P, Other: EUC | Intervention Type: BEHAVIORAL; Name: THPP-P; Assigned to Arm(s): THPP-P | Intervention Type: OTHER; Name: EUC; Assigned to Arm(s): Enhanced Usual Care (EUC), THPP-P
B: Arm Label: Obese patients treated with bariatric surgery; Type: EXPERIMENTAL; Interventions: Procedure: Bariatric surgery | Arm Label: Obese patients not treated with bariatric surgery; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Bariatric surgery; Assigned to Arm(s): Obese patients treated with bariatric surgery
C: Arm Label: Specialty Care; Type: ACTIVE_COMPARATOR; Interventions: Other: psychiatric medications and evidence-based psychotherapies | Arm Label: Integrated Care; Type: EXPERIMENTAL; Interventions: Other: psychiatric medications and evidence-based psychotherapies | Arm Label: Community Clinic Stepped Care; Type: EXPERIMENTAL; Interventions: Other: psychiatric medications and evidence-based psychotherapies | Intervention Type: OTHER; Name: psychiatric medications and evidence-based psychotherapies; Assigned to Arm(s): Community Clinic Stepped Care, Integrated Care, Specialty Care
D: Arm Label: Self Help Plus; Type: EXPERIMENTAL; Interventions: Behavioral: Self Help Plus | Arm Label: Enhanced Treatment As Usual; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Self Help Plus; Assigned to Arm(s): Self Help Plus

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Financial Incentives to Increase Pediatric HIV Testing
Brief Summary: The purpose of this study is to determine whether giving small financial incentives will motivate parents to test their children for HIV.


Options:
A: Arm Label: Nutrition PBF; Type: EXPERIMENTAL; Interventions: Other: Nutrition PBF | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Nutrition PBF; Assigned to Arm(s): Nutrition PBF
B: Arm Label: No incentive; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: KES financial incentive 1; Type: EXPERIMENTAL; Interventions: Behavioral: Financial incentive | Arm Label: KES financial incentive 2; Type: EXPERIMENTAL; Interventions: Behavioral: Financial incentive | Arm Label: KES financial incentive 3; Type: EXPERIMENTAL; Interventions: Behavioral: Financial incentive | Arm Label: KES financial incentive 4; Type: EXPERIMENTAL; Interventions: Behavioral: Financial incentive | Intervention Type: BEHAVIORAL; Name: Financial incentive; Assigned to Arm(s): KES financial incentive 1, KES financial incentive 2, KES financial incentive 3, KES financial incentive 4
C: Intervention Type: BEHAVIORAL; Name: Guideline adherence and financial incentive; Assigned to Arm(s): N/A
D: Arm Label: Performance based incentives; Type: EXPERIMENTAL; Interventions: Behavioral: Performance based incentives | Arm Label: Comparison; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Performance based incentives; Assigned to Arm(s): Performance based incentives

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Appeal and Impact of E-cigarettes in Smokers With Serious Mental Illness
Brief Summary: This study will evaluate behavioral and psychological appeal, toxicity, and effect of e-cigarettes on smoking behavior and nicotine addiction in chronic smokers with serious mental illness (SMI) who have failed to quit smoking. A total of 240 participants will be enrolled and randomly assigned to either receive a supply of e-cigarettes for 8 weeks plus assessments (baseline \& weeks 2, 4, 6, 8, 13, \& 26) or assessments only. This single-blinded study will provide e-cigarettes and instructions on their safe use. Level of appeal will be inferred from carefully assessed use of e-cigarettes and reduction in combustible tobacco. Qualitative data will also be collected from participants assigned to e-cigarettes, given that unanticipated issues will almost certainly arise in connection with e-cigarette use that can only be captured within a qualitative debriefing at the conclusion of participants' time in the study.


Options:
A: Arm Label: Monotherapy (Cytisine only); Type: ACTIVE_COMPARATOR; Interventions: Drug: Cytisine | Arm Label: Monotherapy (Nicotine e-cigarette only); Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine delivered via an e-cigarette | Arm Label: Combination therapy (Cytisine plus a nicotine e-cigarette); Type: ACTIVE_COMPARATOR; Interventions: Combination Product: Cytisine plus nicotine delivered via an e-cigarette | Intervention Type: DRUG; Name: Cytisine; Assigned to Arm(s): Monotherapy (Cytisine only) | Intervention Type: DRUG; Name: Nicotine delivered via an e-cigarette; Assigned to Arm(s): Monotherapy (Nicotine e-cigarette only) | Intervention Type: COMBINATION_PRODUCT; Name: Cytisine plus nicotine delivered via an e-cigarette; Assigned to Arm(s): Combination therapy (Cytisine plus a nicotine e-cigarette)
B: Arm Label: Chantix (varenicline); Type: EXPERIMENTAL; Interventions: Drug: Chantix | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Chantix; Assigned to Arm(s): Chantix (varenicline) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: varenicline | Arm Label: control group; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo tablet is made of lactose | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): varenicline | Intervention Type: DRUG; Name: placebo tablet is made of lactose; Assigned to Arm(s): control group
D: Arm Label: E-Cigarette; Type: EXPERIMENTAL; Interventions: Behavioral: E-cigarette | Arm Label: Assessments only; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: E-cigarette; Assigned to Arm(s): E-Cigarette

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase 2/3, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study To Evaluate the Efficacy and Safety of Certolizumab Pegol in Japanese Subjects With Moderate to Severe Chronic Psoriasis
Brief Summary: The purpose of this study is to demonstrate the efficacy and safety of Certolizumab Pegol (CZP) in the treatment of moderate to severe chronic plaque Psoriasis (PSO) in Japanese subjects.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 4
B: Arm Label: A; Type: EXPERIMENTAL; Interventions: Biological: ABT-874 | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Biological: etanercept | Arm Label: C; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: BIOLOGICAL; Name: ABT-874; Assigned to Arm(s): A | Intervention Type: BIOLOGICAL; Name: etanercept; Assigned to Arm(s): B | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): C
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: CZP 200 mg; Type: EXPERIMENTAL; Interventions: Other: Placebo, Drug: Certolizumab Pegol | Arm Label: CZP 400 mg; Type: EXPERIMENTAL; Interventions: Drug: Certolizumab Pegol | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): CZP 200 mg, Placebo | Intervention Type: DRUG; Name: Certolizumab Pegol; Assigned to Arm(s): CZP 200 mg, CZP 400 mg
D: Arm Label: Apremilast 10mg; Type: EXPERIMENTAL; Interventions: Drug: Apremilast 10mg | Arm Label: Apremilast 20mg; Type: EXPERIMENTAL; Interventions: Drug: Apremilast 20mg | Arm Label: Apremilast 30 mg; Type: EXPERIMENTAL; Interventions: Drug: Apremilast 30 mg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Placebo/Apremilast 20 mg; Type: EXPERIMENTAL; Interventions: Drug: Apremilast 20mg | Arm Label: Placebo/Apremilast 30mg; Type: EXPERIMENTAL; Interventions: Drug: Apremilast 30mg | Intervention Type: DRUG; Name: Apremilast 10mg; Assigned to Arm(s): Apremilast 10mg | Intervention Type: DRUG; Name: Apremilast 20mg; Assigned to Arm(s): Apremilast 20mg | Intervention Type: DRUG; Name: Apremilast 30 mg; Assigned to Arm(s): Apremilast 30 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Apremilast 30mg; Assigned to Arm(s): Placebo/Apremilast 30mg | Intervention Type: DRUG; Name: Apremilast 20mg; Assigned to Arm(s): Placebo/Apremilast 20 mg

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase 2/3, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study To Evaluate the Efficacy and Safety of Certolizumab Pegol in Japanese Subjects With Moderate to Severe Chronic Psoriasis
Brief Summary: The purpose of this study is to demonstrate the efficacy and safety of Certolizumab Pegol (CZP) in the treatment of moderate to severe chronic plaque Psoriasis (PSO) in Japanese subjects.


Options:
A: Arm Label: Cohort 1; Type: EXPERIMENTAL; Interventions: Drug: (CP-6890,550) Tofacitinib, Drug: Placebo | Arm Label: Cohort 2; Type: EXPERIMENTAL; Interventions: Drug: (CP-690,550) Tofacitinib, Drug: Placebo | Intervention Type: DRUG; Name: (CP-6890,550) Tofacitinib; Assigned to Arm(s): Cohort 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 1 | Intervention Type: DRUG; Name: (CP-690,550) Tofacitinib; Assigned to Arm(s): Cohort 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 2
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: CZP 200 mg; Type: EXPERIMENTAL; Interventions: Other: Placebo, Drug: Certolizumab Pegol | Arm Label: CZP 400 mg; Type: EXPERIMENTAL; Interventions: Drug: Certolizumab Pegol | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): CZP 200 mg, Placebo | Intervention Type: DRUG; Name: Certolizumab Pegol; Assigned to Arm(s): CZP 200 mg, CZP 400 mg
C: Arm Label: Active Treatment 10 mg BID; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: Active Treatment 5 mg BID; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: Placebo Treatment; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo/CP-690,550 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Active Treatment 10 mg BID | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Active Treatment 5 mg BID | Intervention Type: DRUG; Name: Placebo/CP-690,550; Assigned to Arm(s): Placebo Treatment | Intervention Type: DRUG; Name: Placebo/CP-690,550; Assigned to Arm(s): Placebo Treatment
D: Arm Label: adalimumab; Type: EXPERIMENTAL; Interventions: Biological: adalimumab | Arm Label: Non-systemic treatment.; Type: ACTIVE_COMPARATOR; Interventions: Device: UVB Phototherapy, Other: Topical treatment | Intervention Type: BIOLOGICAL; Name: adalimumab; Assigned to Arm(s): adalimumab | Intervention Type: DEVICE; Name: UVB Phototherapy; Assigned to Arm(s): Non-systemic treatment. | Intervention Type: OTHER; Name: Topical treatment; Assigned to Arm(s): Non-systemic treatment.

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Immune Benefits of Consumption of Dairy Yogurt Containing Functional Probiotics Among Individuals Over 60 Years Old
Brief Summary: To investigate the impact of consuming dairy yogurt on immun function including natural killer (NK) cell activity, circulating levels of cytokines, and immunoglobulin (Ig) in elderly.


Options:
A: Arm Label: Bifidobacterium animalis subsp. lactis; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Bifidobacterium animalis subsp. lactis | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: Bifidobacterium animalis subsp. lactis; Assigned to Arm(s): Bifidobacterium animalis subsp. lactis
B: Arm Label: Cow's Milk; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Cow's milk | Arm Label: Follow-On Formula; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Follow-On Formula | Intervention Type: DIETARY_SUPPLEMENT; Name: Cow's milk; Assigned to Arm(s): Cow's Milk | Intervention Type: DIETARY_SUPPLEMENT; Name: Follow-On Formula; Assigned to Arm(s): Follow-On Formula
C: Arm Label: Test group; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Probiotic yogurt | Arm Label: Placebo group; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Probiotic yogurt; Assigned to Arm(s): Test group | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo group
D: Arm Label: No probiotics; Type: ACTIVE_COMPARATOR; Interventions: Other: Infant formula | Arm Label: Probiotic; Type: EXPERIMENTAL; Interventions: Other: Infant formula | Intervention Type: OTHER; Name: Infant formula; Assigned to Arm(s): No probiotics | Intervention Type: OTHER; Name: Infant formula; Assigned to Arm(s): Probiotic

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation and Validation of a New Questionnaire to Identify and Quantify Abdominal Symptoms in Patients With Cystic Fibrosis Following FDA Guidelines: the CF Abd-Score (Primarily Named JenAbdomen-CF Score)
Brief Summary: Development, validation and evaluation of a new multimodal questionnaire to assess and quantify the abdominal involvement in patients with the inherited life shortening multi-organ disease Cystic fibrosis.

In the stepwhise development of the patient reported outcome measures (PROM) repeadedly, CF-patients, their families as well as professionals working in different fields of CF-care will be included.


Options:
A: Arm Label: Patients with CF; Type: N/A; Interventions: Diagnostic Test: Questionnaire Patient Reported Outcome Measure (PROM) | Arm Label: Age-matched healthy controls; Type: N/A; Interventions: Diagnostic Test: Questionnaire Patient Reported Outcome Measure (PROM) | Intervention Type: DIAGNOSTIC_TEST; Name: Questionnaire Patient Reported Outcome Measure (PROM); Assigned to Arm(s): Age-matched healthy controls, Patients with CF
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 150 mg Ivacaftor q12h; Type: EXPERIMENTAL; Interventions: Drug: Ivacaftor | Intervention Type: DRUG; Name: Ivacaftor; Assigned to Arm(s): 150 mg Ivacaftor q12h | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: VX-445/TEZ/IVA TC; Type: EXPERIMENTAL; Interventions: Drug: VX-445/TEZ/IVA, Drug: IVA | Intervention Type: DRUG; Name: VX-445/TEZ/IVA; Assigned to Arm(s): VX-445/TEZ/IVA TC | Intervention Type: DRUG; Name: IVA; Assigned to Arm(s): VX-445/TEZ/IVA TC | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Placebo (pooled two times a day [BID]/three times a day [TID]); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo two times a day (BID)/three times a day (TID) | Arm Label: AZLI (pooled two times a day [BID]/three times a day [TID]); Type: EXPERIMENTAL; Interventions: Drug: AZLI 75 mg two times a day (BID)/three times a day (TID) | Intervention Type: DRUG; Name: AZLI 75 mg two times a day (BID)/three times a day (TID); Assigned to Arm(s): AZLI (pooled two times a day [BID]/three times a day [TID]) | Intervention Type: DRUG; Name: Placebo two times a day (BID)/three times a day (TID); Assigned to Arm(s): Placebo (pooled two times a day [BID]/three times a day [TID])

Answer: A